Nidrazid (Isoniazid)

Isoniazid, the active ingredient in Nidrazid, is an antitubercular agent presented as an oral tablet for oral use. It treats tuberculosis in adults and children. It belongs to the class of antimycobacterial agents and is used under prescription for managing Mycobacterium tuberculosis infection.

GNH USA supplies Nidrazid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable sourcing for bulk and finished‑product orders across multiple continents.

Isoniazid is employed in the management of tuberculosis, targeting the Mycobacterium tuberculosis complex.

- Active tuberculosis: used as part of multi‑drug regimens to achieve bacterial eradication and prevent resistance. - Latent tuberculosis infection: administered alone to reduce the risk of progression to active disease. - Pediatric tuberculosis: incorporated into age‑appropriate combination therapy for children diagnosed with TB.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset that may resolve with food. - Peripheral neuropathy: tingling or numbness, often preventable with pyridoxine supplementation. - Rash: skin redness or itching without systemic involvement. - Elevated liver enzymes: mild, transient increase detectable in routine labs.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury presenting with jaundice, fatigue, or abdominal pain. - Allergic reactions: including anaphylaxis, characterized by hives, swelling, and respiratory distress. - Seizures: rare central nervous system events, especially in overdose or pre‑existing conditions.

When prescribing Isoniazid, clinicians should observe several safety measures to minimize risks.

- Monitor liver function: obtain baseline transaminases and repeat periodically during therapy. - Assess for pre‑existing neuropathy: consider pyridoxine supplementation to reduce nerve damage. - Evaluate pregnancy status: use only if benefits outweigh potential risks, as safety data are limited. - Review concomitant medications: avoid drugs that may increase hepatotoxic potential. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Isoniazid interacts with several medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Rifampicin: reduces isoniazid plasma levels, compromising therapeutic effect. - Pyrazinamide: combined use increases risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, carbamazepine): may enhance hepatotoxic risk; monitor liver enzymes. - Oral hypoglycemic agents: isoniazid can potentiate hypoglycemia; check blood glucose. - Warfarin: may increase anticoagulant effect; monitor INR.